{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:26Z","timestamp":1794047486698,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Continuous vaso-occlusive and inflammatory processes cause extensive end-organ damage in adults with sickle cell disease (SCD), and there is little evidence that long-term hydroxyurea therapy prevents this. In initial trials, P-selectin blockade with crizanlizumab reduced SCD vaso-occlusive crisis frequency, and interleukin (IL)-1\u03b2 inhibition in SCD patients, using canakinumab, lowered inflammatory markers. We used murine SCD models to examine the effects of acute and chronic blockade of P-selectin and of IL-1\u03b2 on vaso-occlusive events, their inflammatory profile and organ health. Both approaches improved impaired cutaneous microvascular perfusion in SCD mice by reducing TNF-\u03b1-induced vaso-occlusion. Acute P-selectin blockade markedly reduced TNF-\u03b1-induced neutrophil-platelet aggregate formation in SCD mice, and decreased leukocyte- rolling movements in the microvasculature, while acute IL-1\u03b2 inhibition attenuated microvascular leukocyte adhesion. Six weeks of IL-1\u03b2-blocking immunotherapy improved the inflammatory profile of SCD mice, considerably reduced hepatic fibrosis and provided some relief from lung injury. In contrast, although P-selectin blockade reduced glomerular congestion, no significant benefit to overall organ pathology was observed. Unexpectedly, while combining the two immunotherapies reduced microvascular occlusion, their prolonged use caused acute liver injury. Notably, inhibition of IL-1\u03b2, but not of P-selectin, remarkably decreased hemosiderosis, in association with reduced tissue macrophage infiltration and the correction of biomarkers of dysregulated iron turnover. Our findings suggest that the attenuation of inflammation, as well as of vaso- occlusive processes, may be crucial for mitigating organ damage in SCD. Future trials should explore the ability of cytokine blockade to prevent multi-organ damage in patients with SCD, beyond evaluating vaso-occlusive crisis frequency.<\/jats:p>","DOI":"10.3324\/haematol.2024.286418","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:02:49Z","timestamp":1732186969000},"page":"725-738","source":"Crossref","is-referenced-by-count":5,"title":["Targeting P-selectin and interleukin-1\u03b2 in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition"],"prefix":"10.3324","volume":"110","author":[{"given":"\u00c9rica M. F.","family":"Gotardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiane S.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Cunha","family":"Zaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas F. S.","family":"Gushiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e2mela L.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia C.","family":"Leonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia H.","family":"Pellizzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Millholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Agoulnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Kovarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando F.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Conran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"73341","doi-asserted-by":"crossref","unstructured":"Kato GJ, Piel FB, Reid CD. Sickle cell disease. Nat Rev Dis Primers. 2018; 4:18010.","DOI":"10.1038\/nrdp.2018.10"},{"key":"73342","doi-asserted-by":"crossref","unstructured":"Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010; 376(9757):2018-2031.","DOI":"10.1016\/S0140-6736(10)61029-X"},{"key":"73343","doi-asserted-by":"crossref","unstructured":"Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018; 68:263-299.","DOI":"10.3233\/CH-189012"},{"key":"73344","doi-asserted-by":"crossref","unstructured":"Asare K, Gee BE, Stiles JK. Plasma interleukin-1beta concentration is associated with stroke in sickle cell disease. Cytokine. 2010; 49(1):39-44.","DOI":"10.1016\/j.cyto.2009.10.002"},{"key":"73345","doi-asserted-by":"crossref","unstructured":"Qari MH, Dier U, Mousa SA. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost. 2012; 18(2):195-200.","DOI":"10.1177\/1076029611420992"},{"key":"73346","doi-asserted-by":"crossref","unstructured":"Cerqueira BA, Boas WV, Zanette AD, Reis MG, Goncalves MS. Increased concentrations of IL-18 and uric acid in sickle cell anemia: contribution of hemolysis, endothelial activation and the inflammasome. Cytokine. 2011; 56(2):471-476.","DOI":"10.1016\/j.cyto.2011.08.013"},{"key":"73347","doi-asserted-by":"crossref","unstructured":"Steinberg MH, Barton F, Castro O. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003; 289(13):1645-1651.","DOI":"10.1001\/jama.289.13.1645"},{"key":"73348","doi-asserted-by":"crossref","unstructured":"Ataga KI, Kutlar A, Kanter J. Crizanlizumab in sickle cell disease. N Engl J Med. 2017; 376(18):1796.","DOI":"10.1056\/NEJMc1703162"},{"key":"73349","doi-asserted-by":"crossref","unstructured":"Bennewitz MF, Jimenez MA, Vats R. Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. JCI Insight. 2017; 2(1)","DOI":"10.1172\/jci.insight.89761"},{"key":"73350","doi-asserted-by":"crossref","unstructured":"Karki NR, Kutlar A. P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab. J Pain Res. 2021; 14:849-856.","DOI":"10.2147\/JPR.S278285"},{"key":"73351","unstructured":"Committee for Medicinal Products for Human Use European Medicines Agency (EMA). Adakveo: Authorisation details (21\/8\/2023). 2024."},{"key":"73352","doi-asserted-by":"crossref","unstructured":"Mayer CL, Koeck K, Hottmann M. A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease. Eur J Clin Pharmacol. 2023; 79(9):1219-1228.","DOI":"10.1007\/s00228-023-03514-3"},{"key":"73353","doi-asserted-by":"crossref","unstructured":"Vichinsky E. Chronic organ failure in adult sickle cell disease. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):435-439.","DOI":"10.1182\/asheducation-2017.1.435"},{"key":"73354","doi-asserted-by":"crossref","unstructured":"Hankins JS, Ware RE, Rogers ZR. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005; 106(7):2269-2275.","DOI":"10.1182\/blood-2004-12-4973"},{"key":"73355","doi-asserted-by":"crossref","unstructured":"Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2022; 9(9):CD002202.","DOI":"10.1002\/14651858.CD002202.pub3"},{"key":"73356","doi-asserted-by":"crossref","unstructured":"Rees DC, Kilinc Y, Unal S. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood. 2022; 139(17):2642-2652.","DOI":"10.1182\/blood.2021013674"},{"key":"73357","doi-asserted-by":"crossref","unstructured":"Kaul DK, Thangaswamy S, Suzuka SM. Anti-Interleukin-1 beta antibody-based therapy ameliorates endothelial activation and inflammation in sickle mice. Blood. 2011; 118(21):388.","DOI":"10.1182\/blood.V118.21.848.848"},{"key":"73358","doi-asserted-by":"crossref","unstructured":"Ferreira WA, Chweih H, Lanaro C. Beneficial effects of soluble guanylyl cyclase stimulation and activation in sickle cell disease are amplified by hydroxyurea: in vitro and in vivo studies. J Pharmacol Exp Ther. 2020; 374(3):469-478.","DOI":"10.1124\/jpet.119.264606"},{"key":"73359","doi-asserted-by":"crossref","unstructured":"Jang JE, Hidalgo A, Frenette PS. Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcgammaRIII and SHP-1. Circ Res. 2012; 110(8):1057-1066.","DOI":"10.1161\/CIRCRESAHA.112.266411"},{"key":"73360","doi-asserted-by":"crossref","unstructured":"Dominical VM, Samsel L, Nichols JS. Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia. Haematologica. 2014; 99(11):e214-e217.","DOI":"10.3324\/haematol.2014.108555"},{"key":"73361","doi-asserted-by":"crossref","unstructured":"Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002; 99(5):3047-3051.","DOI":"10.1073\/pnas.052522799"},{"key":"73362","doi-asserted-by":"crossref","unstructured":"Doig K. Introduction to increased destruction of erythrocytes. 2020;316-335.","DOI":"10.1016\/B978-0-323-53045-3.00029-5"},{"key":"73363","doi-asserted-by":"crossref","unstructured":"Niihara Y, Smith WR, Stark CW. A Phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018; 379(19):226-235.","DOI":"10.1056\/NEJMoa1715971"},{"key":"73364","doi-asserted-by":"crossref","unstructured":"Sharpe CC, Suddle A, Stuart-Smith S. An overview of solid organ transplantation in patients with sickle cell disease. Transplantation. 2023; 107(3):596-604.","DOI":"10.1097\/TP.0000000000004305"},{"key":"73365","doi-asserted-by":"crossref","unstructured":"Idowu M, DeBaun MR, Burnett A. Primary analysis of Spartan: a phase 2 trial to assess the efficacy and safety of crizanlizumab in patients with sickle cell disease related priapism. Blood. 2023; 142(Suppl 1):146.","DOI":"10.1182\/blood-2023-179042"},{"key":"73366","doi-asserted-by":"crossref","unstructured":"Idowu M, Garcia RL, Sule OB. Successful treatment of SCD-related priapism with crizanlizumab: a case series. J Investig Med High Impact Case Rep. 2023; 11:23247096231191873.","DOI":"10.1177\/23247096231191873"},{"key":"73367","doi-asserted-by":"crossref","unstructured":"Ghosh S, Flage B, Weidert F, Ofori-Acquah SF. P-selectin plays a role in haem-induced acute lung injury in sickle mice. Br J Haematol. 2019; 186(2):329-333.","DOI":"10.1111\/bjh.15807"},{"key":"73368","doi-asserted-by":"crossref","unstructured":"Vats R, Kaminski TW, Ju EM. P-selectin deficiency promotes liver senescence in sickle cell disease mice. Blood. 2021; 137(19):2676-2680.","DOI":"10.1182\/blood.2020009779"},{"key":"73369","doi-asserted-by":"crossref","unstructured":"van Buul JD, van Rijssel J, van Alphen FP. Inside-out regulation of ICAM-1 dynamics in TNF-alpha-activated endothelium. PLoS One. 2010; 5(6):e11336.","DOI":"10.1371\/journal.pone.0011336"},{"key":"73370","doi-asserted-by":"crossref","unstructured":"Chen Y, Li R, Shang S. Therapeutic potential of TNFalpha and IL1beta blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation. Front Immunol. 2021; 12:623610.","DOI":"10.3389\/fimmu.2021.623610"},{"key":"73371","doi-asserted-by":"crossref","unstructured":"Pratim Das P, Medhi S. Role of inflammasomes and cytokines in immune dysfunction of liver cirrhosis. Cytokine. 2023; 170:156347.","DOI":"10.1016\/j.cyto.2023.156347"},{"key":"73372","unstructured":"Chen H, Yang Y, Zhou X, Feng Y. Attenuating renal interstitial fibrosis by Shenqi pill via reducing inflammation response regulated by NF-kappaB pathway in vitro and in vivo. Iran J Kidney Dis. 2024; 18(2):87-98."},{"key":"73373","doi-asserted-by":"crossref","unstructured":"Duan X, Chen C, Liu X. Interference of periostin attenuates pathological changes, proinflammatory markers and renal fibrosis in diabetic kidney injury. Genes Genomics. 2023; 45(11):1389-1397.","DOI":"10.1007\/s13258-023-01400-x"},{"key":"73374","doi-asserted-by":"crossref","unstructured":"Duvoux C, Blaise L, Matimbo JJ. The liver in sickle cell disease. Presse Med. 2023; 52(4):104212.","DOI":"10.1016\/j.lpm.2023.104212"},{"key":"73375","doi-asserted-by":"crossref","unstructured":"Chen G, Chang J, Zhang D. Targeting Mac-1-mediated leukocyte-RBC interactions uncouples the benefits for acute vaso-occlusion and chronic organ damage. Exp Hematol. 2016; 44(10):940-946.","DOI":"10.1016\/j.exphem.2016.06.252"},{"key":"73376","doi-asserted-by":"crossref","unstructured":"Zhang D, Chen G, Manwani D. Neutrophil ageing is regulated by the microbiome. Nature. 2015; 525(7570):528-532.","DOI":"10.1038\/nature15367"},{"key":"73377","doi-asserted-by":"crossref","unstructured":"Shi J, Fujieda H, Kokubo Y, Wake K. Apoptosis of neutrophils and their elimination by Kupffer cells in rat liver. Hepatology. 1996; 24(5):1256-1263.","DOI":"10.1002\/hep.510240545"},{"key":"73378","doi-asserted-by":"crossref","unstructured":"Rarick KR, Li K, Teng RJ. Sterile inflammation induces vasculopathy and chronic lung injury in murine sickle cell disease. Free Radic Biol Med. 2024; 215:112-126.","DOI":"10.1016\/j.freeradbiomed.2024.01.052"},{"key":"73379","doi-asserted-by":"crossref","unstructured":"Voskaridou E, Douskou M, Terpos E. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol. 2004; 126(5):736-742.","DOI":"10.1111\/j.1365-2141.2004.05104.x"},{"key":"73380","doi-asserted-by":"crossref","unstructured":"Yassin M, Soliman A, De Sanctis V. Liver iron content (LIC) in adults with sickle cell disease (SCD): correlation with serum ferritin and liver enzymes concentrations in transfusion dependent (TD-SCD) and non-transfusion dependent (NT-SCD) patients. Mediterr J Hematol Infect Dis. 2017; 9(1):e2017037.","DOI":"10.4084\/mjhid.2017.037"},{"key":"73381","doi-asserted-by":"crossref","unstructured":"Manci EA, Hillery CA, Bodian CA. Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood. 2006; 107(4):1651-1658.","DOI":"10.1182\/blood-2005-07-2839"},{"key":"73382","doi-asserted-by":"crossref","unstructured":"Williams JD, Kumar R, Afolabi JM, Park F, Adebiyi A. Rhabdomyolysis aggravates renal iron accumulation and acute kidney injury in a humanized mouse model of sickle cell disease. Free Radic Res. 2023; 57:404-412.","DOI":"10.1080\/10715762.2023.2269313"},{"key":"73383","doi-asserted-by":"crossref","unstructured":"Kaminski TW, Sivanantham A, Mozhenkova A. Hemoglobin scavenger receptor CD163 as a potential biomarker of hemolysis induced hepatobiliary injury in sickle cell disease. Am J Physiol Cell Physiol. 2024; 327(2):C423-C437.","DOI":"10.1152\/ajpcell.00386.2023"},{"key":"73384","doi-asserted-by":"crossref","unstructured":"Li H, Kazmi JS, Lee S. Dietary iron restriction protects against vaso-occlusion and organ damage in murine sickle cell disease. Blood. 2023; 141(2):194-199.","DOI":"10.1182\/blood.2022016218"},{"key":"73385","doi-asserted-by":"crossref","unstructured":"Hamdy M, El-Beshlawy A, Verissimo MPA. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: pediatric subgroup analysis of the randomized, open-label FIRST study. Pediatr Blood Cancer. 2024; 71(1):e30711.","DOI":"10.1002\/pbc.30711"},{"key":"73386","doi-asserted-by":"crossref","unstructured":"Katoch O, Ungalara R, Kaminski T. Long-term L-glutamine treatment reduces hemolysis without ameliorating hepatic vasoocclusion and liver fibrosis in a mouse model of sickle cell disease. Biomedicines. 2023; 11(9):2412.","DOI":"10.3390\/biomedicines11092412"},{"key":"73387","doi-asserted-by":"crossref","unstructured":"Federti E, Matte A, Recchiuti A. In humanized sickle cell mice, imatinib protects against sickle cell-related injury. Hemasphere. 2023; 7(3)","DOI":"10.1097\/HS9.0000000000000848"},{"key":"73388","doi-asserted-by":"crossref","unstructured":"Afsar RE, Kanbay M, Ibis A, Afsar B. In-depth review: is hepcidin a marker for the heart and the kidney?. Mol Cell Biochem. 2021; 476(9):3365-3381.","DOI":"10.1007\/s11010-021-04168-4"},{"key":"73389","doi-asserted-by":"crossref","unstructured":"Zheng H, Yang F, Deng K. Relationship between iron overload caused by abnormal hepcidin expression and liver disease: a review. Medicine (Baltimore). 2023; 102(11):e33225.","DOI":"10.1097\/MD.0000000000033225"},{"key":"73390","doi-asserted-by":"crossref","unstructured":"Kowdley KV, Gochanour EM, Sundaram V, Shah RA, Handa P. Hepcidin signaling in health and disease: ironing out the details. Hepatol Commun. 2021; 5(5):723-735.","DOI":"10.1002\/hep4.1717"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11840\/77798","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11840\/78119","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11840\/77798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:39Z","timestamp":1794046059000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286418","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}